Celyad Oncology SA (FRA:1C0)

Market Cap	10.03M +0.4%
Revenue (ttm)	7.00K -96.2%
Net Income	3.30M
EPS	0.07
Shares Out	n/a
PE Ratio	2.44
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	420
Open	0.1680
Previous Close	0.1850
Day's Range	0.1680 - 0.1680
52-Week Range	0.1285 - 0.4550
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 24, 2027

About Celyad Oncology

Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 5
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1C0

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error